Conexeu Sciences (CNXU) Registration filing summary

Company overview and business model

• Focuses on developing a patented, temperature-responsive collagen-based scaffold (CXU™) for regenerative tissue applications in wound care, aesthetics, dentistry, veterinary medicine, and 3D bioprinting.

• Originated from academic research at the University of British Columbia, with exclusive global patent rights acquired in 2025.

• CXU™ is in preclinical development, designed to transition from liquid to gel in situ, supporting tissue integration and healing.

• Business model targets staged regulatory clearance, initial commercialization in wound care, and expansion into multiple verticals.

• Plans to leverage a single material backbone for multiple indications, aiming for operational efficiency and broad market reach.

Financial performance and metrics

• No revenues generated to date; company remains in pre-commercial, development stage.

• Net loss of $3.92M for the year ended October 31, 2025, up from $0.47M in 2024, reflecting increased R&D and business development.

• Cash and cash equivalents of $6.26M as of January 31, 2026, with working capital of $6.58M.

• Raised over $10.1M in equity and warrant exercises from November 2024 to January 2026.

• Accumulated deficit of $6.24M as of January 31, 2026; substantial doubt exists about ability to continue as a going concern without further financing.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of registered shares; proceeds from warrant exercises (up to $1.67M) will be used for operations.

• Capital allocation priorities: FDA 510(k) submission ($1.62M), manufacturing scale-up ($0.25M), and market entry/pilot program ($0.23M) over the next 18 months.

• Additional funds required for commercialization, expanded clinical studies, and manufacturing readiness.